Nonclinical models for antituberculosis drug development: a landscape analysis.

Gumbo, Tawanda; Lenaerts, Anne J; Hanna, Debra; Romero, Klaus; Nuermberger, Eric

Gumbo, Tawanda; Lenaerts, Anne J; Hanna, Debra; Romero, Klaus; Nuermberger, Eric.

Afiliação

Gumbo T; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas Department of Medicine, University of Cape Town, South Africa.
Lenaerts AJ; Department of Microbiology, Immunology, and Pathology, Colorado State University, Ft. Collins.
Hanna D; Critical Path Institute, Tucson, Arizona.
Romero K; Critical Path Institute, Tucson, Arizona.
Nuermberger E; Center for Tuberculosis Research, Johns Hopkins University, Baltimore, Maryland.

J Infect Dis ; 211 Suppl 3: S83-95, 2015 Jun 15.

Article em En | MEDLINE | ID: mdl-26009617

Assuntos

Antituberculosos/farmacologia; Antituberculosos/uso terapêutico; Tuberculose/tratamento farmacológico; Animais; Modelos Animais de Doenças; Combinação de Medicamentos; Humanos; Tuberculose/microbiologia

Palavras-chave

antituberculosis; drug development; drug regimen design; guinea pig tuberculosis model; hollow fiber system model of tuberculosis; mouse tuberculosis model

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tuberculose / Antituberculosos Tipo de estudo: Guideline Limite: Animals / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google